Target intelligence / Profile preview

Mucosal T lymphocytes

Molecular classification
Other (Cell type), Immune cell
01

Overview

Mucosal T lymphocytes are a specialized subset of T cells located within the mucosal linings of the body, particularly the gastrointestinal, respiratory, and urogenital tracts (StatPearls, Mucosal Immunity). These cells are divided into two main compartments: intraepithelial lymphocytes (IELs), which reside within the epithelial layer, and lamina propria lymphocytes (LPLs), found in the underlying connective tissue (Nature Reviews Immunology, 2013). They serve as a primary defense mechanism, maintaining mucosal barrier integrity and responding to commensal and pathogenic microbes through cytokine secretion and direct cytotoxicity (PubMed, PMID: 23903472). In pathological conditions such as Crohn's disease and ulcerative colitis, dysregulated recruitment and activation of these cells lead to chronic tissue damage (Journal of Crohn's and Colitis, 2017). Modern therapeutic interventions target the homing receptors on these cells, such as integrin alpha-4 beta-7, to selectively inhibit their migration into inflamed mucosal tissues, thereby providing a localized anti-inflammatory effect (NEJM, 2013). While effective, this approach is considered a cell-population-level target rather than a single molecular target, as it involves various receptors and signaling pathways (FDA Label, Entyvio).

Other names
Intraepithelial lymphocytesLamina propria lymphocytesGALT T cellsMucosa-associated T cellsGut-homing T cells
02

Mechanism of action

Inhibition of lymphocyte trafficking to mucosal tissues by blocking adhesion molecules (e.g., Integrin alpha-4 beta-7) or chemokine receptors (e.g., CCR9) required for extravasation and homing (NEJM, 2013; Nature Reviews Immunology, 2013).

03

Biological functions

Immune responseMucosal immunityCytokine productionCytotoxicityImmune surveillance
04

Disease associations

Inflammatory bowel diseaseCrohn's diseaseUlcerative colitisCeliac diseaseHIV infectionFood allergy
05

Safety considerations

Increased risk of enteric infections (e.g., Clostridioides difficile)Progressive multifocal leukoencephalopathy (PML) (associated with non-selective alpha-4 blockade)Infusion-related reactionsNasopharyngitis
06

Interacting drugs

Vedolizumab

4 more in the full profile.

07

Biomarkers

Integrin alpha-4 beta-7CD103CCR9CD4CD8MAdCAM-1 (ligand)

Beyond the preview

Go deeper on Mucosal T lymphocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucosal T lymphocytes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call